Robinhood Asset Management LLC Takes $11.18 Million Position in Natera, Inc. $NTRA

Robinhood Asset Management LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA) during the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 41,175 shares of the medical research company’s stock, valued at approximately $11,177,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Integrated Wealth Concepts LLC increased its stake in Natera by 6.6% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 96 shares in the last quarter. NewEdge Advisors LLC boosted its position in Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after purchasing an additional 1,847 shares in the last quarter. Focus Partners Wealth boosted its position in Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after purchasing an additional 474 shares in the last quarter. Sivia Capital Partners LLC purchased a new stake in Natera during the second quarter worth $298,000. Finally, WINTON GROUP Ltd acquired a new stake in Natera in the second quarter valued at $558,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Activity

In other Natera news, insider John Fesko sold 295 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $267.99, for a total value of $79,057.05. Following the completion of the transaction, the insider directly owned 183,774 shares in the company, valued at approximately $49,249,594.26. The trade was a 0.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Burkes Brophy sold 478 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $274.22, for a total value of $131,077.16. Following the transaction, the chief financial officer directly owned 51,637 shares in the company, valued at approximately $14,159,898.14. This represents a 0.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 181,045 shares of company stock worth $41,330,968 in the last three months. 5.05% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

NTRA has been the subject of a number of research analyst reports. Royal Bank Of Canada raised their price target on Natera from $275.00 to $350.00 and gave the company an “outperform” rating in a research report on Friday, August 7th. TD Cowen increased their price objective on shares of Natera from $325.00 to $340.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Leerink Partners set a $330.00 target price on shares of Natera in a report on Friday, August 7th. The Goldman Sachs Group began coverage on shares of Natera in a research report on Friday, June 5th. They set a “neutral” rating and a $245.00 target price for the company. Finally, Wall Street Zen downgraded shares of Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $319.38.

Natera Trading Up 2.2%

Shares of NTRA stock opened at $332.03 on Friday. The company has a market capitalization of $47.86 billion, a price-to-earnings ratio of -244.14 and a beta of 1.51. The firm has a 50-day moving average price of $274.24 and a 200 day moving average price of $229.39. Natera, Inc. has a twelve month low of $157.43 and a twelve month high of $333.56.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same period last year, the company earned ($0.74) EPS. As a group, research analysts predict that Natera, Inc. will post -1.02 earnings per share for the current year.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.